Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
A triple combination targeting epigenetic dysregulation and apoptotic resistance, comprising iadademstat (LSD1 inhibitor), azacitidine (a hypomethylating agent), and venetoclax (a BCL-2 inhibitor), is under investigation in a phase I trial for acute myeloid leukemia (NCT06357182)
Temperature indicator alerts you if cooling is needed
Model selection using modified AIC and BIC in joint modeling of paired functional data
Feng, Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE/ mice
Treatment begins with 0.25 mg administered subcutaneously once weekly for four weeks, serving primarily as a tolerance-building dose rather than a therapeutic one
US$ 28.56
US$ 21.09
US$ 23.12
US$ 22.15
